Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 01-Oct-24 4:15 PM View:  | Paulson John Director | Valeant Pharmaceuticals Int... (BHC) | 30-Sep-24 | Grant | 7,659 | $8.16 | $62,497.40 | 3% 252.64K to 260.3K | |
| 01-Oct-24 4:17 PM View: | Wechsler Amy B Director | Valeant Pharmaceuticals Int... (BHC) | 30-Sep-24 | Grant | 842 | $8.16 | $6,870.72 | < 1% 206.25K to 207.09K | |
| 01-Oct-24 4:16 PM View: | Icahn Brett Director | Valeant Pharmaceuticals Int... (BHC) | 30-Sep-24 | Grant | 4,059 | $8.16 | $33,121.40 | 3% 148.61K to 152.67K | |
| 09-Sep-24 4:54 PM View: | Carson Seana EVP, General Counsel | Valeant Pharmaceuticals Int... (BHC) | 06-Sep-24 | Sale (Planned) | 13,370 | $6.21 | $83,027.70 | (3%) 448.57K to 435.2K | |
| 09-Sep-24 4:54 PM View: | Carson Seana EVP, General Counsel | Valeant Pharmaceuticals Int... (BHC) | 05-Sep-24 | Payment of Exercise | 51,337 | $6.19 | $317,776.00 | (10%) 499.9K to 448.57K | |
| 09-Sep-24 4:37 PM View: | Barresi John S SVP, Controller & CAO | Valeant Pharmaceuticals Int... (BHC) | 05-Sep-24 | Payment of Exercise | 3,982 | $6.19 | $24,648.60 | (3%) 154.39K to 150.41K | |
| 03-Sep-24 4:21 PM View: | Appio Thomas Chief Executive Officer Director | Valeant Pharmaceuticals Int... (BHC) | 30-Aug-24 | Payment of Exercise | 14,683 | $5.93 | $87,070.20 | (1%) 1.37M to 1.35M | |
| 21-Aug-24 4:11 PM View: | Charhon Jean-Jacques EVP, CFO | Valeant Pharmaceuticals Int... (BHC) | 19-Aug-24 | Grant | 298,838 | -- | -- | 100% 0 to 298.84K | |
| 19-Jul-24 4:34 PM View: | Barresi John S SVP, Controller & CAO | Valeant Pharmaceuticals Int... (BHC) | 18-Jul-24 | Grant | 49,254 | -- | -- | 47% 105.13K to 154.39K | |
| 17-Jul-24 4:12 PM View: | Lenar Aimee J. EVP, US Pharma | Valeant Pharmaceuticals Int... (BHC) | 15-Jul-24 | Grant | 144,352 | -- | -- | 100% 0 to 144.35K | |
| 01-Jul-24 4:45 PM View: | Paulson John Director | Valeant Pharmaceuticals Int... (BHC) | 28-Jun-24 | Grant | 8,967 | $6.97 | $62,500.00 | 4% 243.67K to 252.64K | |
| 20-May-24 6:04 PM View: | Wechsler Amy B Director | Valeant Pharmaceuticals Int... (BHC) | 17-May-24 | Grant | 35,360 | -- | -- | 21% 169.91K to 205.27K | |
| 20-May-24 6:01 PM View: | Power Robert N Director | Valeant Pharmaceuticals Int... (BHC) | 17-May-24 | Grant | 35,360 | -- | -- | 21% 165.02K to 200.38K | |
| 20-May-24 5:59 PM View: | Paulson John Director | Valeant Pharmaceuticals Int... (BHC) | 17-May-24 | Grant | 35,360 | -- | -- | 17% 208.31K to 243.67K | |
| 20-May-24 5:43 PM View: | Icahn Brett Director | Valeant Pharmaceuticals Int... (BHC) | 17-May-24 | Grant | 35,360 | -- | -- | 33% 108.5K to 143.86K | |
| 21-May-24 4:08 PM View: | Lee Frank D. Director | Valeant Pharmaceuticals Int... (BHC) | 17-May-24 | Grant | 35,360 | -- | -- | 100% 0 to 35.36K | |
| 20-May-24 5:46 PM View: | Kavanagh Sarah B Director | Valeant Pharmaceuticals Int... (BHC) | 17-May-24 | Grant | 35,360 | -- | -- | 24% 146.65K to 182.01K | |
| 20-May-24 5:49 PM View: | Miller Steven D Director | Valeant Pharmaceuticals Int... (BHC) | 17-May-24 | Grant | 35,360 | -- | -- | 24% 149.52K to 184.88K | |
| 21-May-24 4:09 PM View: | Garcia Christian A Director | Valeant Pharmaceuticals Int... (BHC) | 17-May-24 | Grant | 35,360 | -- | -- | 100% 0 to 35.36K | |
| 01-Apr-24 4:33 PM View: | Paulson John Director | Valeant Pharmaceuticals Int... (BHC) | 29-Mar-24 | Grant | 5,890 | $10.61 | $62,492.90 | 3% 202.42K to 208.31K | |
| 01-Apr-24 4:31 PM View: | Icahn Brett Director | Valeant Pharmaceuticals Int... (BHC) | 29-Mar-24 | Grant | 3,122 | $10.61 | $33,124.40 | 3% 105.38K to 108.5K | |
| 01-Apr-24 4:30 PM View: | Robertson Russel C Director | Valeant Pharmaceuticals Int... (BHC) | 29-Mar-24 | Grant | 2,945 | $10.61 | $31,246.40 | 1% 222.33K to 225.28K | |
| 01-Apr-24 4:29 PM View: | Wechsler Amy B Director | Valeant Pharmaceuticals Int... (BHC) | 29-Mar-24 | Grant | 647 | $10.61 | $6,864.67 | < 1% 169.26K to 169.91K | |
| 04-Mar-24 4:16 PM View: | Carson Seana EVP, General Counsel | Valeant Pharmaceuticals Int... (BHC) | 04-Mar-24 | Sale (Planned) | 6,313 | $9.80 | $61,867.40 | (1%) 506.22K to 499.9K | |
| 04-Mar-24 4:19 PM View: | Appio Thomas Chief Executive Officer Director | Valeant Pharmaceuticals Int... (BHC) | 01-Mar-24 | Payment of Exercise | 116,982 | $9.89 | $1,156,950.00 | (8%) 1.49M to 1.37M | |
| 04-Mar-24 4:24 PM View: | Barresi John S SVP, Controller & CAO | Valeant Pharmaceuticals Int... (BHC) | 01-Mar-24 | Payment of Exercise | 3,188 | $9.89 | $31,529.30 | (3%) 110.25K to 107.06K | |
| 04-Mar-24 4:16 PM View: | Carson Seana EVP, General Counsel | Valeant Pharmaceuticals Int... (BHC) | 01-Mar-24 | Payment of Exercise | 24,243 | $9.89 | $239,763.00 | (5%) 530.46K to 506.22K | |
| 04-Mar-24 4:19 PM View: | Appio Thomas Chief Executive Officer Director | Valeant Pharmaceuticals Int... (BHC) | 29-Feb-24 | Grant | 519,328 | -- | -- | 54% 967.01K to 1.49M | |
| 04-Mar-24 4:16 PM View: | Carson Seana EVP, General Counsel | Valeant Pharmaceuticals Int... (BHC) | 29-Feb-24 | Grant | 147,536 | -- | -- | 39% 382.93K to 530.46K | |
| 04-Mar-24 4:24 PM View: | Barresi John S SVP, Controller & CAO | Valeant Pharmaceuticals Int... (BHC) | 29-Feb-24 | Grant | 39,126 | -- | -- | 55% 71.13K to 110.25K | |
| 02-Jan-24 4:19 PM View: | Robertson Russel C Director | Valeant Pharmaceuticals Int... (BHC) | 29-Dec-23 | Grant | 3,896 | $8.02 | $31,245.90 | 2% 218.44K to 222.33K | |
| 02-Jan-24 4:15 PM View: | Wechsler Amy B Director | Valeant Pharmaceuticals Int... (BHC) | 29-Dec-23 | Grant | 857 | $8.02 | $6,873.14 | < 1% 168.4K to 169.26K | |
| 02-Jan-24 4:16 PM View: | Paulson John Director | Valeant Pharmaceuticals Int... (BHC) | 29-Dec-23 | Grant | 7,793 | $8.02 | $62,499.90 | 4% 194.63K to 202.42K | |
| 02-Jan-24 4:18 PM View: | Icahn Brett Director | Valeant Pharmaceuticals Int... (BHC) | 29-Dec-23 | Grant | 4,130 | $8.02 | $33,122.60 | 4% 101.25K to 105.38K | |
| 05-Dec-23 4:35 PM View: | Carson Seana EVP, General Counsel | Valeant Pharmaceuticals Int... (BHC) | 05-Dec-23 | Sale (Planned) | 220 | $7.38 | $1,623.60 | (< 1%) 383.14K to 382.93K | |
| 05-Dec-23 4:35 PM View: | Carson Seana EVP, General Counsel | Valeant Pharmaceuticals Int... (BHC) | 01-Dec-23 | Payment of Exercise | 1,691 | $7.36 | $12,445.80 | (< 1%) 384.84K to 383.14K | |
| 06-Nov-23 5:06 PM View: | Carson Seana EVP, General Counsel | Valeant Pharmaceuticals Int... (BHC) | 06-Nov-23 | Sale (Planned) | 43 | $7.61 | $327.23 | (< 1%) 384.88K to 384.84K | |
| 06-Nov-23 5:06 PM View: | Carson Seana EVP, General Counsel | Valeant Pharmaceuticals Int... (BHC) | 03-Nov-23 | Payment of Exercise | 334 | $7.57 | $2,528.38 | (< 1%) 385.21K to 384.88K | |
| 02-Oct-23 4:27 PM View: | Paulson John Director | Valeant Pharmaceuticals Int... (BHC) | 29-Sep-23 | Grant | 7,603 | $8.22 | $62,496.70 | 4% 187.02K to 194.63K | |
| 02-Oct-23 4:25 PM View: | Icahn Brett Director | Valeant Pharmaceuticals Int... (BHC) | 29-Sep-23 | Grant | 4,029 | $8.22 | $33,118.40 | 4% 97.22K to 101.25K | |
| 02-Oct-23 4:28 PM View: | Robertson Russel C Director | Valeant Pharmaceuticals Int... (BHC) | 29-Sep-23 | Grant | 3,801 | $8.22 | $31,244.20 | 2% 214.64K to 218.44K | |
| 02-Oct-23 4:29 PM View: | Wechsler Amy B Director | Valeant Pharmaceuticals Int... (BHC) | 29-Sep-23 | Grant | 836 | $8.22 | $6,871.92 | < 1% 167.57K to 168.4K | |
| 06-Sep-23 4:33 PM View: | Carson Seana EVP, General Counsel | Valeant Pharmaceuticals Int... (BHC) | 06-Sep-23 | Sale (Planned) | 6,685 | $8.28 | $55,351.80 | (2%) 391.9K to 385.21K | |
| 06-Sep-23 4:31 PM View: | Barresi John S SVP, Controller & CAO | Valeant Pharmaceuticals Int... (BHC) | 05-Sep-23 | Payment of Exercise | 3,982 | $8.35 | $33,249.70 | (5%) 75.11K to 71.13K | |
| 06-Sep-23 4:29 PM View: | Vadaketh Tom George EVP, Chief Financial Officer | Valeant Pharmaceuticals Int... (BHC) | 05-Sep-23 | Payment of Exercise | 43,948 | $8.35 | $366,966.00 | (7%) 608.88K to 564.93K | |
| 06-Sep-23 4:33 PM View: | Carson Seana EVP, General Counsel | Valeant Pharmaceuticals Int... (BHC) | 05-Sep-23 | Payment of Exercise | 51,337 | $8.35 | $428,664.00 | (12%) 443.24K to 391.9K | |
| 05-Sep-23 5:09 PM View: | Appio Thomas Chief Executive Officer Director | Valeant Pharmaceuticals Int... (BHC) | 01-Sep-23 | Payment of Exercise | 14,111 | $8.46 | $119,379.00 | (1%) 981.12K to 967.01K | |
| 05-Jul-23 4:06 PM View: | Paulson John Director | Valeant Pharmaceuticals Int... (BHC) | 30-Jun-23 | Grant | 7,812 | $8.00 | $62,496.00 | 4% 179.21K to 187.02K | |
| 05-Jul-23 4:07 PM View: | Icahn Brett Director | Valeant Pharmaceuticals Int... (BHC) | 30-Jun-23 | Grant | 4,140 | $8.00 | $33,120.00 | 4% 93.08K to 97.22K | |
| 05-Jul-23 4:01 PM View: | Robertson Russel C Director | Valeant Pharmaceuticals Int... (BHC) | 30-Jun-23 | Grant | 3,906 | $8.00 | $31,248.00 | 2% 210.73K to 214.64K |
